| A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia (NCT05304377) | Enliven Therapeutics | 2022-05-22 |
| FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia (NCT05152537) | Affiliated Hospital of Nantong University | 2021-01-01 |
| Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase (NCT05926128) | Fundaleu | 2019-02-01 |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. (NCT03578367) | Novartis Pharmaceuticals | 2018-11-22 |
| Palatability (Taste) of Oral Formulations of Bosutinib (NCT03747679) | Pfizer | 2018-11-22 |
| Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium (NCT03678454) | Incyte Biosciences Benelux | 2017-02-03 |
| Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy (NCT03880617) | National Taiwan University Hospital | 2015-03-25 |
| A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation (NCT01744665) | Novartis Pharmaceuticals | 2013-08-12 |
| Treatment Modification Based on Early Assessment of CML Patients (NCT01762969) | Rabin Medical Center | 2013-01-01 |
| An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints (NCT01216085) | Novartis Pharmaceuticals | 2010-08-01 |
| Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) (NCT01019317) | M.D. Anderson Cancer Center | 2009-11-01 |
| A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia (NCT00964873) | Synta Pharmaceuticals Corp. | 2009-08-01 |
| STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders (NCT00858572) | Synta Pharmaceuticals Corp. | 2009-03-01 |
| Tasigna in Glivec-resistant or Intolerant Patients in CML (NCT01206088) | Novartis Pharmaceuticals | 2009-02-01 |
| Umbilical Cord Blood Transplant for Hematological Malignancies (NCT00891592) | University of Pennsylvania | 2009-01-01 |
| Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) (NCT00815568) | Samsung Medical Center | 2008-08-01 |
| Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant (NCT00684008) | Cytheris, Inc. | 2008-03-01 |
| Sirolimus in Combination With MEC in High Risk Myeloid Leukemias (NCT00780104) | Abramson Cancer Center at Penn Medicine | 2007-07-01 |
| Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies (NCT00776373) | Abramson Cancer Center at Penn Medicine | 2007-01-01 |
| CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation (NCT00333190) | Dana-Farber Cancer Institute | 2005-09-01 |
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies (NCT00013533) | National Cancer Institute (NCI) | 2001-03-14 |
| Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders (NCT00511537) | University of California, San Francisco | 1999-01-01 |